| 000 | 01244 a2200265 4500 | ||
|---|---|---|---|
| 005 | 20250518065504.0 | ||
| 264 | 0 | _c20201130 | |
| 008 | 202011s 0 0 eng d | ||
| 022 | _a1873-7560 | ||
| 024 | 7 |
_a10.1016/j.eururo.2019.09.015 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSingla, Nirmish | |
| 245 | 0 | 0 |
_aRe: Brian I. Rini, Thomas Powles, Michael B. Atkins, et al. Atezolizumab plus Bevacizumab Versus Sunitinib in Patients with Previously Untreated Metastatic Renal Cell Carcinoma (IMmotion151): A Multicentre, Open-label, Phase 3, Randomised Controlled Trial. Lancet 2019;393:2404-15: Putting IMmotion into Motion: Personalizing Frontline Treatment for Metastatic Renal Cell Carcinoma. _h[electronic resource] |
| 260 |
_bEuropean urology _c06 2020 |
||
| 300 |
_ae168-e169 p. _bdigital |
||
| 500 | _aPublication Type: Letter; Comment | ||
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 | _aBevacizumab |
| 650 | 0 | 4 |
_aCarcinoma, Renal Cell _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aKidney Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aSunitinib |
| 773 | 0 |
_tEuropean urology _gvol. 77 _gno. 6 _gp. e168-e169 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.eururo.2019.09.015 _zAvailable from publisher's website |
| 999 |
_c30263005 _d30263005 |
||